Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faslodex vs Arimidex in Advanced Breast Cancer
NCT00635713Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 1997
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of fulvestrant in breast cancer (3 arms), sponsored by AstraZeneca. Primary endpoint: Time to Tumor Progression. Started May 1997; status: completed.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00635713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00635713.